Antiemetic Drug Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2023-2027

Antiemetic Drug Market Forecast 2023-2027

The Global antiemetics drugs market size is estimated to grow by USD 1.63 billion at a compound annual growth rate (CAGR) of 6.47% between 2022 and 2027. The increase in the prevalence of nausea and vomiting stands as a pivotal driver molding the market landscape. These distressing symptoms afflict millions worldwide, stemming from various illnesses and treatments. With cancer diagnoses escalating and advancements in therapy, a burgeoning number of patients endure chemotherapy-induced nausea and vomiting (CINV). The quest for potent antiemetic drugs to mitigate CINV and enhance patients' treatment journey intensifies. Additionally, motion sickness plagues many travelers, whether for work or leisure, contributing to nausea and vomiting occurrences. Consequently, patients necessitate antiemetic medications to effectively manage these symptoms, fostering positive market growth prospects. A comprehensive analysis delves into drivers, trends, and obstacles, shedding light on the market dynamics.

What will be the size of the Antiemetic Drug Market During the Forecast Period?

To learn more about this report, Request Free Sample

Antiemetic medications or drugs play a pivotal role in gastroenteritis treatments, a focus area emphasized by entities like the American Cancer Society addressing both new cancer cases and cancer deaths. Online platforms and the ever-expanding realm of e-commerce, driven by the penetration of smartphones and the internet, include online pharmacies. In-depth drug type insights encompass the serotonin-receptor antagonists segment with prominent drugs like Ondansetron (Zofran), Dolasetron (Anzemet), and Granisetron (Kytril). 

Market Segmentation 

The drug market is witnessing significant growth driven by various factors, such as the widespread use of opioid analgesics and radiation therapy. Patients undergoing treatment for cancer, metabolic disorders, or post-operative surgery often experience nausea and vomiting as side effects, necessitating the use of antiemetic drugs. Moreover, conditions like food poisoning, dehydration, and esophageal tears can also lead to severe nausea and vomiting, further boosting the demand for antiemetic medications. The market is supported by ongoing investments in research and development to improve drug efficacy and dosage formulations. However, patent expiration and regulatory restraints pose challenges to market growth despite estimations of increased usage in hospital pharmacies and surgical procedures. Furthermore, the Technavio market growth analysis report has segmented the market into Application, Drug, and Geography.

Application Analysis 

The market share growth by the chemotherapy segment will be significant during the forecast period. Chemotherapy drugs are effective at removing cancer cells, but they can also be harmful to normal cell types, such as those in the gut and vomiting centers of the brain. The goal of antiemetic therapy in CINV is to provide effective control of nausea and vomiting, allowing patients to tolerate and complete their chemotherapy treatments without interruptions or dose reductions.

Get a glance at the market contribution of various segments View a PDF Sample

The chemotherapy segment was valued at USD 1.64 billion in 2017. The management of CINV typically involves a combination of antiemetic medications targeting multiple pathways involved in the development of nausea and vomiting. Thus, growing cases of cancer globally will drive the demand for chemotherapy, which, in turn, will boost the growth of the market in focus on the chemotherapy segment during the forecast period.

Drug Class Analysis 

The 5-HT3 receptor antagonists segment will account for the largest share of this segment. 5-HT3 receptor antagonists are a commonly used class of drugs in the management of nausea and vomiting. They work by blocking serotonin activity in the fiveHT3 receptor, which is present in both the gastrointestinal and central nervous systems. By inhibiting the activation of these receptors, 5-HT3 receptor antagonists help reduce the sensation of nausea and the occurrence of vomiting. The growing use of 5-HT3 receptor antagonists will drive the growth of this segment in the market focus during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period.

North America held the largest share of the market in 2022. North America comprises countries such as the US, Canada, and Mexico, and it represents a key region for the development, manufacturing, and consumption of antiemetic drugs, which is driving the growth of the regional market. Several of the leading pharmaceuticals are based in North America, developing and manufacturing antiepileptic medicines. These companies invest in research and development to introduce innovative drugs with improved efficacy and safety profiles.

Buy Now Full Report and Discover More

Key  Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market players, including:

Boehringer Ingelheim International GmbH - The company offers an antiemetic drug, namely OFEV.

• Algen Healthcare Ltd.
• Bristol Laboratories Ltd.
• Cadila Pharmaceuticals Ltd.
• Cipla Ltd.
• Eagle Pharmaceuticals Inc.
• Fresenius SE and Co. KGaA
• GlaxoSmithKline Plc
• Helsinn Healthcare SA
• Heron Therapeutics Inc.
• Lupin Ltd.
• Merck and Co. Inc.
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• RedHill Biopharma Ltd.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Key Drivers, Trends, Challenges, and Customer Landscape

The antiemetic drug market encompasses a wide range of medications used to prevent and alleviate symptoms of vomiting and nausea. These medications are essential for managing various conditions, including rotavirus gastroenteritis and postoperative surgery. The market for antiemetic drugs is significant, with major retail pharmacies such as CVS Pharmacy, Walgreens Boots Alliance, and Rite Aid, among others, stocking a variety of antiemetic options.

Generic substitutes play a crucial role in the antiemetic drug market, providing affordable alternatives to branded medications. For instance, Barhemsys, a recently FDA-approved antiemetic, is available in both branded and generic forms. The Association of Anesthetists recognizes the importance of antiemetic drugs in managing anesthesia-related nausea and vomiting. Overall, the antiemetic drug market continues to evolve, with ongoing research and development efforts aimed at improving existing treatments and discovering new ones. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Market Drivers

The increasing healthcare expenditure is a key driver shaping the market. Global health expenditure is driven by factors like population growth, aging demographics, technological progress, and the prevalence of chronic diseases. As healthcare systems invest more in providing comprehensive medical care, the demand also experiences a parallel increase. The growth of the worldwide market for antiepileptic drugs is underpinned by increasing access to healthcare and coverage.

However, as more individuals gain access to healthcare services, the demand for various medications increases. Improved access to healthcare allows patients to seek timely and appropriate treatment for conditions that may cause nausea and vomiting, leading to the rising need for antiemetics. In addition, driving health expenditure and, consequently, demand for antiemetic medicinal products is also played out by government initiatives and insurance programs that promote better access to healthcare. As healthcare becomes more accessible and affordable, patients can access essential medications, such as antiemetics, without financial barriers, which will contribute to the growth of the market in focus during the forecast period.

Market Trends

The rising demand in emerging economies is a primary trend in the market.  A significant trend in the global pharmaceutical market is the rising demand for antiepileptic drugs in developing countries. Emerging economies are experiencing an increase in the prevalence of diseases and conditions that cause nausea and vomiting. The rising incidence of cancer, gastrointestinal disorders, infectious diseases, and the use of chemotherapy regimens contribute to the higher demand for effective antiemetic drugs. In order to improve the outcomes and quality of life for patients, an increased emphasis has been placed on addressing symptoms such as nausea and vomiting when developing healthcare systems in these countries.

Additionally, there is a growing awareness of healthcare and increased accessibility to medical services in emerging economies. Patients are becoming more informed about their healthcare needs and seeking better management of their symptoms, including nausea and vomiting. The growth of healthcare infrastructure in emerging economies plays a significant role in driving demand for antiemetics. The availability and use of those medicinal products are enhanced by the presence of well-equipped health facilities and trained healthcare professionals. Thus, the growing demand in emerging economies is one of the emerging trends that is expected to drive the market growth and trends.

 Market Challenges

High entry barriers for new players are major challenges impeding the growth of the market. Due to the presence of larger market players, it is far from easy for SMEs to come up with novel products that can penetrate the market. In addition, a significant role in the market scenario is played by switching costs for buyers as well as the trust of public companies. Also, these bigger companies have large distribution channels and operate in collaboration with all the major leading hospitals and health centers, which poses a big challenge for newer companies to penetrate the market. Leading companies such as Pfizer Inc and Novartis AG have big brand images.

Therefore, customers show resistance toward the adoption of newer products. The major undertakings also offer a wide range of products that are typically impossible to compete with the new and developing players. With various products to choose from, buyers tend to incline more on these bigger companies that have higher brand values. Smaller companies also have limited resources and funding, with no major collaborators. With fewer products in the line, if approvals get delayed every time, it comes as a major drawback since product launch delays will have an impact on vendors' revenues. Thus, high entry barriers for new players are expected to pose a negative impact on the market during the forecast period.

Buy Now Full Report and Discover More

Market Customer Landscape

The Market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Market Customer Landscape

Market Analyst Overview 

Serotonin receptor antagonists, such as Sancuso manufactured by Cumberland Pharmaceuticals, are essential medications used to prevent nausea and vomiting (emesis) in children undergoing chemotherapies. The effectiveness and safety of Sancuso were recently studied and published in the Official Journal of the American Academy of Pediatrics. The Centers for Disease Control and Prevention (CDC) emphasizes the importance of managing chemotherapy-induced emesis to ensure optimal treatment outcomes and improve patients' quality of life. Sandoz, a leading pharmaceutical company, also offers similar serotonin receptor antagonists to help alleviate symptoms of chemotherapy-induced ailments, including vertigo, in adult patients. These drugs or medications play a crucial role in mitigating the adverse effects of chemotherapies, enhancing patients' overall well-being.

In the healthcare sector, the National Library of Medicine is a valuable resource for researching various medical topics, including frontiers in neuroscience and the use of dopamine receptor antagonist drugs. One such drug is Fosaprepitant, which is used to prevent nausea and vomiting caused by chemotherapy. General anesthetics, another important topic, can also lead to side effects like dizziness and emotional stress. Cancer statistics highlight the need for effective treatments and medications, such as antihistamines and anticholinergics, which can alleviate symptoms and improve patient comfort. Gravisetron, a serotonin antagonist, is another medication used to prevent nausea and vomiting. Surgeries, a common application of anesthetics, can also lead to side effects, making it crucial to understand the mechanisms of these drugs and their potential interactions.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Application Outlook
  • Chemotherapy
  • Surgery
  • Gastroenteritis
  • Others

• Drug Class Outlook
  • 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist
  • Dopamine antagonist
  • Neurokinin-1 (NK 1) receptor antagonist
  • Cannabinoid receptor antagonist
  • Others
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • Asia
    • Australia
    • Argentina
    • Rest of the World 

Market Scope
Report Coverage	Details
Page number	179
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 6.47%
Market growth 2023-2027	USD 1.63 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	5.44
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 37%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Algen Healthcare Ltd., Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eagle Pharmaceuticals Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our market growth analysis report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this  Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market research and growth between 2023 and 2027
• Precise estimation of the size of the market in focus on the parent market analysis and report.
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Vendor landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on vendor position and Classification
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of drug market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch